Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
Sun Pharmaceutical Industries is set to boost its presence in Japan as a specialty pharma in dermatology, regardless of the type of products - whether it be brand-name drugs or generics - looking to eventually make a foray into the…
To read the full story
Related Article
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
November 28, 2018
- Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
September 7, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…